Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACARBOSE vs ALFUZOSIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in individuals with impaired glucose tolerance
Treatment of benign prostatic hyperplasia (BPH),Off-label: Management of ureteral stones (medical expulsive therapy)
Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
Terminal elimination half-life is approximately 2.5 to 3 hours for the parent compound, but the drug acts locally in the GI tract; systemic half-life is not clinically relevant for its pharmacodynamic effect.
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Acarbose is metabolized exclusively within the gastrointestinal tract, primarily by intestinal bacteria and digestive enzymes. Approximately 35% of the dose is absorbed as metabolites, which are excreted via the kidneys. The parent drug is not significantly metabolized by hepatic enzymes.
Extensively metabolized in the liver, primarily via CYP3A4, to inactive metabolites.
Primarily excreted unchanged in feces (approximately 50% of an oral dose) and as metabolites via the gastrointestinal tract; less than 2% of the dose is recovered in urine as active drug or metabolites. Renal excretion is minimal.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Negligible to low protein binding; less than 1-2% bound to plasma proteins, primarily albumin.
82-90% bound to human serum albumin and alpha-1-acid glycoprotein.
Volume of distribution is not well defined due to minimal systemic absorption; estimated to be less than 0.3 L/kg, reflecting limited distribution beyond the gastrointestinal lumen.
Approximately 2.5-3.2 L/kg; indicates extensive extravascular distribution.
Oral: Systemic bioavailability is very low (approximately 0.5-2%) due to local action in the GI tract and minimal absorption. The drug acts locally in the intestine; systemic levels are negligible.
Oral immediate-release: 64% (first-pass metabolism); extended-release: 49% relative to immediate-release.
No specific dose adjustment required for GFR ≥25 m L/min; contraindicated in GFR <25 m L/min (creatinine clearance <25 m L/min).
For Cr Cl 30-49 m L/min: 10 mg once daily; for Cr Cl <30 m L/min: contraindicated.
No specific dose adjustment for mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment (Child-Pugh class C).
Child-Pugh A: 10 mg once daily; Child-Pugh B or C: contraindicated.
Not recommended for use in pediatric patients; safety and efficacy not established.
Not established; safety and efficacy in children <18 years have not been studied.
Initiate at the lowest dose (25 mg 3 times daily); titrate slowly based on tolerance and glycemic control, as elderly patients may have reduced renal function and higher risk of gastrointestinal adverse effects.
No specific dose adjustment recommended; monitor for orthostatic hypotension and dizziness.
None
None.
Risk of hepatotoxicity: rare cases of severe hepatocellular injury, including fulminant hepatitis, reported, especially at higher doses (≥300 mg/day); monitor liver enzymes periodically.,Use with caution in patients with renal impairment (e GFR <25 m L/min/1.73 m²): insufficient data; avoid use.,May cause hypoglycemia when used in combination with sulfonylureas or insulin; treat hypoglycemia with oral glucose (dextrose) rather than sucrose (acarbose inhibits sucrose digestion).,Gastrointestinal adverse effects (flatulence, diarrhea, abdominal pain) are common due to undigested carbohydrate fermentation in the colon; may subside with continued use.,Acute porphyria: acarbose has been associated with acute attacks in susceptible patients.
Risk of hypotension, especially orthostatic hypotension, particularly with dose initiation or increase,May cause syncope, especially in patients with predisposing factors (e.g., hypovolemia, concurrent antihypertensives),Use with caution in patients with hepatic impairment,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on or previously treated with alpha-1 blockers,Should not be used in combination with other alpha-1 blockers
Hypersensitivity to acarbose or any component of the formulation,Diabetic ketoacidosis,Cirrhosis or significant hepatic impairment,Inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Renal impairment (e GFR <25 m L/min/1.73 m²)
Hypersensitivity to alfuzosin hydrochloride or any component of the formulation,Concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir),Moderate to severe hepatic impairment (Child-Pugh B or C)
Acarbose delays digestion of complex carbohydrates and sucrose. To reduce gastrointestinal side effects, avoid high-sucrose foods and drinks. Simple sugars like glucose and fructose can still be absorbed and used to treat hypoglycemia. Alcohol may increase the risk of hypoglycemia when combined with acarbose, especially if taken with other antidiabetic agents.
Take with food to reduce the risk of hypotension. Avoid grapefruit juice as it may increase alfuzosin levels. High-fat meals may alter absorption; consistency in meal timing is advised.
Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposure. Risk cannot be excluded in first trimester. Second and third trimester: no known fetal risks, but use only if clearly needed.
Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. First trimester: no evidence of fetal harm from animal data. Second and third trimesters: potential risk of maternal hypotension affecting uteroplacental perfusion; limited human data available.
Acarbose is excreted into breast milk in negligible amounts due to low oral bioavailability and high molecular weight. M/P ratio not established. Considered compatible with breastfeeding; monitor infant for gastrointestinal effects (e.g., flatulence, diarrhea).
It is unknown if alfuzosin is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised due to potential for adverse effects in nursing infants, including hypotension. Alternative agents with more safety data are preferred during breastfeeding.
No dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to minimal systemic absorption. Initiate at 25 mg three times daily with meals; titrate based on 1-hour postprandial glucose levels.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. However, increased plasma volume during pregnancy may reduce drug levels; clinical effect should be monitored. Use lowest effective dose if necessary, and avoid in patients with severe hypotension or hypovolemia.
Acarbose delays carbohydrate absorption by inhibiting alpha-glucosidase in the brush border of the small intestine. It should be taken with the first bite of each main meal. Its efficacy is limited by gastrointestinal side effects (flatulence, diarrhea) due to undigested carbohydrates reaching the colon. Not recommended in patients with inflammatory bowel disease or colonic obstruction. Hypoglycemia from acarbose (rare in monotherapy) must be treated with oral glucose or milk, not sucrose or complex carbohydrates, since their digestion is blocked. Acarbose can cause isolated transaminase elevations; monitor LFTs if symptoms occur.
Alfuzosin is a selective alpha-1 adrenergic antagonist used for benign prostatic hyperplasia (BPH). It has fewer cardiovascular side effects than other alpha-blockers due to its higher affinity for alpha-1a receptors in the prostate. Do not use in patients with moderate to severe hepatic impairment. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Use with caution in patients with prolonged QT interval or on QT-prolonging drugs. Administer after the same meal each day to reduce first-dose syncope.
Take acarbose with the first bite of each main meal; do not take it between meals.,Common side effects include gas, bloating, and diarrhea, which may improve over time.,If you experience low blood sugar, treat it with glucose tablets, juice, or regular soda, not candy or fruit juice (acarbose blocks their digestion).,Tell your doctor if you develop jaundice or abdominal pain, as liver problems can occur.,This medication is not for weight loss and does not affect insulin secretion.
Take this medication immediately after a meal at the same time each day.,Avoid situations that may cause dizziness or fainting, especially after the first dose or when increasing dose.,Do not crush, chew, or open the tablet; swallow whole.,Do not drive or operate heavy machinery until you know how the medication affects you.,Inform your doctor if you experience severe dizziness, fainting, or irregular heartbeat.,Avoid alcohol, which can increase dizziness and blood pressure-lowering effects.,Do not take with other alpha-blockers or medications for erectile dysfunction without consulting your doctor.
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the gut, leading to a reduction in postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity in some patients, potentially increasing the risk of hypoglycemia when combined with acarbose. The interaction is primarily due to additive effects on glucose metabolism, and patients should be monitored for signs of hypoglycemia, particularly during initiation or dose adjustments."
"Chlorothiazide, a thiazide diuretic, can decrease the therapeutic efficacy of acarbose, an alpha-glucosidase inhibitor used for postprandial glycemic control in type 2 diabetes. The hypokalemia induced by chlorothiazide may impair insulin secretion and reduce the glucose-lowering effect of acarbose, potentially leading to elevated postprandial glucose levels. This interaction may necessitate dose adjustments or alternative antihyperglycemic therapy to maintain glycemic control."
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, thereby reducing postprandial hyperglycemia. Selegiline, a selective MAO-B inhibitor at therapeutic doses, can potentiate the hypoglycemic effect of acarbose by an unknown pharmacodynamic mechanism, potentially leading to episodes of hypoglycemia. This interaction is of particular concern in patients with diabetes mellitus who are co-prescribed these agents, as the combined effect on glucose homeostasis may require dose adjustments or enhanced monitoring."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, can enhance the antihypertensive effect of Benidipine, a dihydropyridine calcium channel blocker. This occurs through additive vasodilation, potentially leading to excessive reductions in blood pressure. Clinically, patients may experience orthostatic hypotension, dizziness, or syncope, particularly during initial co-administration or dose adjustments."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, may potentiate the hypotensive effects of lamotrigine, an anticonvulsant. This interaction is primarily due to additive vasodilation, leading to an increased risk of orthostatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or with dose adjustments. Patients, especially those with cardiovascular comorbidities, should be monitored for blood pressure changes and symptoms of hypotension."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, reduces peripheral vascular resistance by blocking alpha-1 receptors on vascular smooth muscle. Pentolinium, a ganglionic blocker, inhibits sympathetic outflow by competitively blocking nicotinic acetylcholine receptors at autonomic ganglia, leading to pronounced hypotension. When combined, their additive vasodilatory effects can cause excessive hypotension, increased risk of syncope, dizziness, and potential cardiovascular collapse, especially during initial therapy or dose escalation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACARBOSE vs ALFUZOSIN HYDROCHLORIDE, answered by our medical review team.
ACARBOSE is a Alpha-Glucosidase Inhibitor that works by Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.. ALFUZOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACARBOSE and ALFUZOSIN HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACARBOSE is: Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.. The standard adult dose of ALFUZOSIN HYDROCHLORIDE is: 10 mg orally once daily immediately after the same meal each day. Extended-release tablet.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACARBOSE and ALFUZOSIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACARBOSE is classified as Category C. Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposu. ALFUZOSIN HYDROCHLORIDE is classified as Category C. Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregn. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.